TRiNDS

Next week the New Horizons: Duchenne UK Conference 2025 is taking place in London, March 28-29! This conference is a valuable opportunity to stay up-to-date on the latest developments in Duchenne Muscular Dystrophy (DMD) research, treatments, and technology. TRiNDS CEO Lauren Morgenroth will be participating in the conference and looks forward to engaging with attendees, learning from the latest insights, and exploring how we can further support advancements in DMD care in the UK. If you’re interested in connecting with TRiNDS, email us at [email protected]. We look forward to seeing you in London!

Please join us in welcoming Jasmine Campbell to TRiNDS! Jasmine lives in Lancaster, Pennsylvania, 4 hours east of TRiNDS headquarters in Pittsburgh, Pennsylvania. Jasmine brings with her 12+ years of clinical trial experience. In her time away from work Jasmine is passionate about writing and travel. We’re thrilled to have her on our team! #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

We’re thrilled to announce that TRiNDS CEO, Lauren Morgenroth, and Lead Data Manager, Abby Loden, will be attending the Muscular Dystrophy Association Conference 2025 from March 16–19. Both Lauren and Abby are excited to connect with the incredible community of physicians, researchers, industry leaders, and patient organizations who are coming together to advance research and care for neuromuscular diseases. Make sure to stop by booth #516 during the conference to learn more about how we’re supporting clinical trials in the rare neuromuscular disease space. Whether you’re a sponsor, healthcare provider, or part of the rare disease community, we’d love to meet you and discuss how we can collaborate to create meaningful change. We can’t wait to see you there! #MDA2025 #MDAConference #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

Today, we take a moment to celebrate our truly exceptional people that make TRiNDS successful. Their resilience, expertise, and commitment drive progress in the rare neuromuscular disease space. From navigating complex clinical operations to building meaningful connections with patient communities, every team member plays a crucial role in advancing research and supporting patients. In recognition of Employee Appreciation Day, we’re giving our employees the day off to relax and recharge — a small way to show gratitude for their hard work and the impact they make every day. We are continually inspired by their dedication and proud of all they accomplish. Here’s to our team — thank you for making TRiNDS a place of passion and purpose! #EmployeeAppreciationDay2025 #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

On this Rare Disease Day 2025, we reaffirm our commitment to the rare disease community by focusing on what we do best—driving progress through research. Rare neuromuscular diseases often come with unique complexities, but they also bring opportunities for innovation, collaboration, and meaningful impact. Today, we honor the resilience of patients, families, and caregivers navigating these conditions. We also shine a light on the researchers, sponsors, and advocates working tirelessly to create better outcomes for those affected. At TRiNDS, we are proud to stand alongside this incredible community, leveraging our expertise in rare neuromuscular diseases to support clinical trials, advance therapies, and move closer to life-changing solutions. Rare is not invisible. Rare is not impossible. Together, we can continue to make a difference. #RareDiseaseDay2025 #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

In one week, TRiNDS CEO, Lauren Morgenroth, is headed to Rome, Italy, for the 2025 International Conference on Duchenne and Becker Muscular Dystrophy hosted by Parent Project Muscular Dystrophy (PPMD). ? This key event plays an essential role in sharing the latest advancements in research and treatment with the Italian Duchenne and Becker muscular dystrophy communities. It brings together individuals from across these communities—researchers, clinicians, industry experts, patients, and advocates—who are all committed to sharing knowledge, broadening perspectives, and improving care. ? If you're attending and would like to connect, please reach out—we’d love to explore ways to work together! Send us an email at [email protected]

Rare neuromuscular diseases present unique challenges in clinical research—varying patient populations, unpredictable disease progression, and the need for specialized assessments. At TRiNDS we thrive in this complex space because we’ve built our expertise around it. What makes makes us different: ? Established due to unmet needs for dedicated neuromuscular research provider with partial ownership from patient organizations. ? Understanding and experience in being flexible and creative to reduce clinical trial participant burden. ?Learned experience from past neuromuscular programs. ? Individualized solutions needed for neuromuscular and rare disease research. In rare disease research, every detail matters. By combining tailored solutions with our deep expertise, we help our sponsors move closer to new treatments and brighter futures for patients. If you’re interested in working with us, please contact [email protected]

Since our founding in 2016 TRiNDS has been driven by a singular mission: advancing research for rare neuromuscular diseases. Over the years, our dedication has led to incredible milestones. We’re proud to have supported a clinical trial that achieved FDA drug approval—an accomplishment that underscores the trust sponsors place in our expertise. We then completed an FDA inspection with no action indicated (NAI), a testament to the quality, precision, and integrity we bring to every project. This journey has been one of growth, collaboration, and unwavering commitment to improving patient outcomes. Thank you to our sponsors, partners, and team members who continue to help us make a difference in rare neuromuscular research. Learn more about the Path of TRiNDS on our website https://trinds.com/ #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

This week TRiNDS Director of Clinical Operations & Quality Management Andrea D’Alessandro is attending SCOPE Summit 2025 taking place in Orlando, Florida.?SCOPE is a hub of innovation and TRiNDS is grateful to be a part of the conversations shaping the future of the industry. #SCOPESummit2025 #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

February 1st marked the beginning of Black History Month. TRiNDS is committed to fostering inclusivity. The challenges of rare neuromuscular diseases impact people of all backgrounds. Let’s celebrate Black leaders, scientists, advocates, and patients in their advancement within healthcare. #BlackHistoryMonth #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch